DB
LRMR icon

Dmitry Balyasny’s Larimar Therapeutics LRMR Stock Holding History

Dmitry Balyasny’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.9K Buy
+17,006
New +$67.5K ﹤0.01% 2903
2025
Q4 		– Sell
-286,533
Closed -$926K – 3353
2025
Q3 		$926K Buy
+286,533
New +$1.07M ﹤0.01% 2147
2025
Q1 		– Sell
-79,496
Closed -$308K – 3077
2024
Q4 		$308K Buy
+79,496
New +$525K ﹤0.01% 2373
2019
Q1 		– Sell
-45,690
Closed -$2.71M – 1528
2018
Q4 		$2.71M Sell
45,690
-29,414
-39% -$2.9M 0.02% 635
2018
Q3 		$10.5M Buy
75,104
+29,266
+64% +$3.55M 0.05% 476
2018
Q2 		$5.63M Buy
45,838
+7,329
+19% +$623K 0.03% 632
2018
Q1 		$3.44M Buy
+38,509
New +$3.26M 0.01% 821
2016
Q4 		– Sell
-40,002
Closed -$1.59M – 1428
2016
Q3 		$1.59M Sell
40,002
-21,423
-35% -$973K 0.01% 638
2016
Q2 		$4.42M Buy
61,425
+57,258
+1,374% +$4.53M 0.03% 535
2016
Q1 		$334K Buy
4,167
+400
+11% +$31.6K ﹤0.01% 986
2015
Q4 		$284K Sell
3,767
-262
-7% -$42.1K ﹤0.01% 986
2015
Q3 		$1.54M Buy
+4,029
New +$1.82M 0.01% 692

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Dmitry Balyasny's LRMR Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Larimar Therapeutics (LRMR) in Q2 2026: 17,006 shares worth $51.9K. The stake represents ﹤0.01% of the portfolio and ranks #2903 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in LRMR as recently as Q3 2025.

Dmitry Balyasny first reported a position in LRMR in Q3 2015 and has held it in 12 quarters since. The position peaked at $10.5M in Q3 2018. 161 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Dmitry Balyasny held 17,006 shares of Larimar Therapeutics worth $51.9K as of Q2 2026.
  • Larimar Therapeutics was a new Dmitry Balyasny position in Q2 2026.
  • Larimar Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2903 holding.
  • Dmitry Balyasny first reported a position in Larimar Therapeutics in Q3 2015 and has held it in 12 quarters since.
  • Dmitry Balyasny's Larimar Therapeutics position peaked at $10.5M in Q3 2018.
  • 161 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.